Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06412198 · ClinicalTrials.gov registry record · Phase 1
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
A Phase 1 study of Metastatic Colorectal Cancer and KRAS G12C Mutations, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 2
- Study locations
NCT06412198 is a Phase 1 study of Metastatic Colorectal Cancer and KRAS G12C Mutations that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants, below the 185-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06412198, a Phase 1 study of Metastatic Colorectal Cancer and KRAS G12C Mutations, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 2
- Study locations
Study Summary
To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG Cetuximab
- DRUG Adagrasib
Study Locations (2)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2029-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06412198
The ClinicalTrials.gov registry entry for NCT06412198 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 185-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (83% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cemiplimab is the first listed.
NCT06412198 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT06412198 about?
NCT06412198 is a clinical study titled "A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations". To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
What is the current status of trial NCT06412198?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2024-08-28. Estimated completion is 2029-03-01.
What conditions does trial NCT06412198 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer, KRAS G12C Mutations.
What interventions are being tested in trial NCT06412198?
The interventions under investigation include: Cemiplimab (DRUG), Cetuximab (DRUG), Adagrasib (DRUG).
Who is sponsoring clinical trial NCT06412198?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06412198 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
RECRUITING · Phase 1
-
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.